stockrowVerrica Pharmaceuticals Inc.
VRCA Healthcare Biotechnology
Verrica Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $35.6 million, up 370.2% from fiscal 2024.
- Revenue
- −53.9%
- EPS
- −3,200.0%
- Free cash flow
- +7.63%
- Total debt
- −97.9%
Quarter to June 2026, against a year earlier
Follow VRCA
Alert me
Verrica Pharmaceuticals Inc. (VRCA) EV/Sales
As of 6 November 2026, Verrica Pharmaceuticals Inc. (VRCA) trades at a EV/Sales of 2.3×. Over the past ten years it has ranged from 0.0× (September 2022) to 92.3× (December 2023); the current reading is higher than 56% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.0× | (56.10%) |
| FY2024 | 4.6× | (91.73%) |
| FY2023 | 55.3× | 661.22% |
| FY2022 | 7.3× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 4.4× | 54.43% |
| Mar 2026 | 2.8× | 40.79% |
| Dec 2025 | 2.0× | 13.62% |
| Sep 2025 | 1.8× | (64.25%) |
| 15 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| KLRS Kalaris Therapeutics Inc. compare | n/m |
| BOLD Boundless Bio, Inc. compare | n/m |
| RNTX Rein Therapeutics Inc. compare | n/m |
| ELOX Senesco Technologies Inc. compare | n/m |
| ALPS Alps Group Inc. compare | n/m |
| INKT MiNK Therapeutics, Inc. compare | n/m |
| HRTX Heron Therapeutics, Inc. compare | 1.0× |
| VRCA Verrica Pharmaceuticals Inc. | 2.3× |
| RNXT RenovoRx, Inc. compare | 17.8× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)